Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism

FASEB Journal

Volumn 20, Issue 13, 2006, Pages 2302-2312

  Duka, Tetyana ^a   Rusnak, Milan ^a   Drolet, Robert E ^b   Duka, Valeriy ^a   Wersinger, Christophe ^a   Goudreau, John L ^b   Sidhu, Anita ^a,c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

synuclein knock out mice; Alzheimer's disease; Mesencephalic neurons; Neurodegeneration; PD

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; SERINE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSKELETON; EXPERIMENTAL MODEL; IMMUNOPRECIPITATION; MALE; MESENCEPHALON; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MPTP POISONING; PHOSPHORYLATION; TAU PROTEINS; TRANSFECTION;

EID: 33845643466     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-6092com     Document Type: Article

References (62)

1. Morris, H. R. (2005) Genetics of Parkinson's disease. Ann Med. 37, 86-96
2. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, O., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
3. Pandey, N., Schmidt, R. E., and Galvin, J. E. (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp. Neurol. 197, 515-520
4. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841
5. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
6. Clayton, D. F., and George, J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129
7. Lotharius, J., and Brundin, P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 12, 932-942
8. Perez, R.G., and Hastings, T. G. (2004) Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem. 89, 1318-1324
9. Sidhu, A., Wersinger, C., and Vernier, P. (2004a) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 18, 637-647
10. Sidhu, A., Wersinger, C., and Vernier, P. (2004b) Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett. 565, 1-5
11. Goedert, M., and Spillantini, M. G. (1998) Lewy body diseases and multi-system atrophy as alpha-synucleopathies. Mol. Psychiatry 3, 462-465
12. Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909
13. Fornai, F., Schluter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., and Battaglia, G. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102, 3413-3418
14. Ishizawa, T., Mattila, P., Davies, P., Wang, D., and Dickson, D. W. (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 62, 389-397
15. Kotzbauer, P. T., Trojanowski, J. Q., and Lee., V. M. (2001) Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. 17, 225-32
16. Lippa, C. F., Schmidt, M. L., Lee, V. M.-Y., and Trojanowski, J. Q. (1999) Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357
17. Arima, K., Hirai, S., Sunohara, N., Aoto, K., Izumiyama, Y., Uéda, K., Ikeda, K., and Kawai, M. (1999) Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843, 53-61
18. Iseki, E., Marui, W., Kosaka, K., and Uéda, K. (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disese. Neurosci. Lett. 265, 9-12
19. Friedhoff, P., von Bergen, M., Mandelkow, E. M., and Mandelkow, E. (2000) Structure of tau protein and assembly into paired helical filaments. Biochim Biophys. Acta. 1502, 122-132
20. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M.,and Crowther, R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U. S. A. 97, 4897-4902
21. Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotsbauer, P. T., Trojanowski, J. Q., and Lee, V. M. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640
22. Kotzbauer, P. T., Giasson, B. I., Kravitz, A. V., Golbe, L. I., Mark, M. H., Trojanowski, J. Q., and Lee, V. M. (2004) Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp. Neurol. 187, 279-288
23. Drechsel, D. N., Hyman, A. A., Cobb, M. H., and Kirschner, M. W. (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Cell Bio. 3, 1141-1154
24. Biernat, J., Gustke, N., Drewes, G., Mandelkow, E. M., and Mandelkow, F. (1993) Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11, 153-163
25. Michaelis, M. L., Dobrowsky, R. T., and Li, G. (2002) Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 19, 289-293
26. Buee, L., Bussiere, T., Buee-Scherrer, V., and Delacourte, A. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130
27. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39
28. Alonso, A.C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881
29. Morishima-Kawashima, M., and Ihara, Y. (2002) Alzheimer's disease: beta-Amyloid protein and tau. J. Neurosci. Res. 70, 392-401
30. Johnson, G. V., and Stoothoff, W. H. (2004) Tau phosphorylation in neuronal cell function and dysfunction. J. Cell Sci. 17, 5721-57219
31. Ikura, Y., Kudo, T., Tanaka, T., Tanii, H., Grundke-Iqbal, I., Iqbal, K., and Takeda, M. (1998) Levels of tau phosphorylation at different sites in Alzheimer disease brain. Neuroreport 9, 2375-2379
32. Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V. M. (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10, 1089-1099
33. Seubert P., Mawal-Dewan, M., Barbour, R., Jakes, R., Goedert, M., Johnson, G. V., Litersky, J. M., Schenk, D., Lieberburg, I., Trojanowski, J. Q., et al. (1995) Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 270, 18917-18922
34. Otvos, L. Jr., Feiner, L., Lang, E., Szendrei, G. L., Goedert, M., and Lee, V. M. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669-673
35. Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V., Berry, R. W., Kuret, J., and Binder, L. I. (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 21, 3737-3745
36. Drolet, R.E., Behrouz, B., Lookingland, K. J., and Goudreau, J. L. (2004) Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25, 761-769
37. Wersinger, C., Prou, D., Vernier, P., and Sidhu, A. (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151-2153
38. Palkovits, M. (1973) Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res. 59, 449-450
39. Lindley, S. E., Lookingland, K. J., and Moore, K. E. (1990) Dopaminergic and beta-adrenergic receptor control of alpha-melanocyte-stimulating hormone secretion during stress. Neuroendocrinology 52, 46-51
40. Loo, D. T., and Rillema, J. R. (1998) Measurement of cell death. Methods Cell Biol. 57, 251-264
41. Sahara, N., Lewis, J., DeTure, M., McGowan, E., Dickson, D. W., Hutton, M., and Yen, S. H. (2002) Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem. 83, 1498-1508
42. Frasier, M., Walzer, M., McCarthy, L., Magnuson, D., Lee, J. M., Haas, C., Kahle, P., and Wolozin, B. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P a-synuclein. Exp. Neurol. 192, 274-287
43. Gomez-Santos, C., Ferrer, I., Reiriz, J., Vinals, F., Barrachina, M., and Ammbrosio, S. (2002) MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935, 32-39
44. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., and Ihara, Y. (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829
45. Hanger, D. P., Betts, J. C., Loviny, T. L., Blackstock, W. P., and Anderton, B. H. (1998) J. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476
46. Payton, J. E., Perrin, R. J., Clayton, D. F., and George, J. M. (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res. Mol. Brain Res. 95, 138-145
47. Alim, M. A., Ma, Q. L., Takeda, K., Aizawa, T., Matsubara, M., Nakamura, M., Asada, A., Saito, T., Kaji, H., Yoshii, M., et al. (2004) Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimer's Dis. 6, 435-442
48. Wersinger, C., and Sidhu, A. (2005) Disruption of the interaction of α-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44, 13612-13624
49. Jensen, P. H., Hager, H., Nielsen, M. S., Hojrup, P., Gliemann, J., and Jakes, R. (1999) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25481-25489
50. Benussi, L., Ghidoni, R., Paterlini, A., Nicosia, F., Alberici, A. C., Signorini, S., Barbiero, L., and Binetti, G. (2005) Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp. Cell Res. 308, 78-84
51. Dauer, W., Kholodilov, N., Vila, M., Trillat, A. C., Goodchild, R., Larsen, K.E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99, 14524-14529
52. Schlüter, O.M., Fornai, F., Alessandri, M.G., Takamori, S., Geppert, M., Jahn R., and Sudhof, T. C. (2003) Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118, 985-1002
53. Purisai, M. G., McCormack, A. L., Langston, W. J., Johnston, L. C., and DiMonte, D. A. (2005) alpha-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20, 898-906
54. Mandel, S., Maor, G., and Youdim, M. B. (2004) Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-pigallo-catechin-3-gallate. J. Mol. Neurosci. 24, 401-416
55. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001) Neurodegenerative tauopathies Annu. Rev. Neurosci. 24, 1121-1159
56. Goedert, M., Spillantini, M. G., Cairns, N. J., and Crowther, R. A. (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159-168
57. Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M., and Przedborski, S. (2000) alpha-Synuclein upregulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J. Neurochem. 74, 721-729
58. Kuhn, K., Wellen, J., Link, N., Maskri, L., Lubbert, H., and Tichel, C. C. (2003) The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17, 1-12
59. Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., and Lau Y.-S. (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956, 156-165
60. Xu, Z., Cawthon, D., McCastlain, K. A., Slikker, W., Jr., and Ali, S. F. (2005) Selective alterations of gene expression in mice induced by MPTP. Synapse 55, 45-51
61. Du, H., Tang, L., Luo, X., Li, H.., Hu, J., Zhou, J., and Hu, H. Y. (2003) A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 29, 8870-8878
62. Iqbal, K., and Grundke-Iqbal, I. (2005) Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol. (Berl.) 109, 25-31